HealthDay - Drugs for Restless Legs Syndrome Have Downsides
The drugs that are widely used to treat restless legs syndrome do provide relief, but they are burdened by side effects and a gradual loss of effectiveness that causes many sufferers to stop taking them, a new analysis finds.
“One of the things that we found that we can’t fully explain is that they have more robust effects early in therapy,” said study co-author C. Michael White, an associate professor of pharmacy practice at the University of Connecticut School of Pharmacy. The report was published in the May/June issue of the Annals of Family Medicine .
Related Results
GSK faces approval delay.
GSK wins restless leg race
Research and Markets: The Parkinsons Disease Market Is Set To Continue To Gro…
PPSI wins SW Argus press revamp work
Pinguin sauve une usine anglaise de legumes surgeles. (En Manchete Dans Ce Nu…
White and his colleagues looked at 14 trials of four nonergot dopamine agonist (NEDA) drugs, one of which never reached the market. The other three, pramipexole (Mirapex), ropinirole (Requip) and rotigotine (Neupro) are the mainstays of treatment for a condition that affects 5 percent to 10 percent of American adults.
“This kind …
Read the full article with a Free Trial at MyWire.
